Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-22T02:08:16.851Z Has data issue: false hasContentIssue false

What is the neurobiology of schizophrenia?

Published online by Cambridge University Press:  30 October 2024

Michael A. Cummings*
Affiliation:
University of California, Irvine, CA, USA University of California, Riverside, CA, USA
Ai-Li W. Arias
Affiliation:
University of California, Irvine, CA, USA University of California, Riverside, CA, USA
Stephen M. Stahl
Affiliation:
University of California, San Diego, CA, USA University of Cambridge, Cambridge, UK
*
Corresponding author: Michael A. Cummings; Email: [email protected]
Rights & Permissions [Opens in a new window]

Abstract

Schizophrenia spectrum disorders are brain diseases that are developmental dementias (dementia praecox). Their pathology begins in utero with psychosis most commonly becoming evident in adolescence and early adulthood. It is estimated they afflict the U.S. population at a prevalence rate of approximately 0.8%. Genetic studies indicate that these brain diseases are about 80% determined by genes and about 20% determined by environmental risk factors. Inheritance is polygenic with some 270 gene loci having been identified as contributing to the risk for schizophrenia. Interestingly, many of the identified gene loci and gene polymorphisms are involved in brain formation and maturation. The identified genetic and epigenetic risks give rise to a brain in which neuroblasts migrate abnormally, assume abnormal locations and orientations, and are vulnerable to excessive neuronal and synaptic loss, resulting in overt psychotic illness. The illness trajectory of schizophrenia then is one of loss of brain mass related to the number of active psychotic exacerbations and the duration of untreated illness. In this context, molecules such as dopamine, glutamate, and serotonin play critical roles with respect to positive, negative, and cognitive domains of illness. Acutely, antipsychotics ameliorate active psychotic illness, especially positive signs and symptoms. The long-term effects of antipsychotic medications have been debated; however, the bulk of imaging data suggest that antipsychotics slow but do not reverse the illness trajectory of schizophrenia. Long-acting injectable antipsychotics (LAI) appear superior in this regard. Clozapine remains the “gold standard” in managing treatment-resistant schizophrenia.

Type
Review
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press

Schizophrenia spectrum disorders are a cluster of psychotic brain diseases that afflict approximately 0.4% to nearly 2.0% of persons in various worldwide populations.Reference Kahn, Sommer and Murray 1 , Reference McGrath, Saha, Chant and Welham 2 In 2019, the direct and indirect annual costs of schizophrenia were estimated at $343.2 billion in the United States alone.Reference Kadakia, Catillon and Fan 3 Moreover, in addition to a substantial economic burden on society as a whole, the schizophrenia spectrum disorders impose a variety of devastating personal and familial burdens, including but not limited to social isolation, disruption of education, unemployment, homelessness, intrafamilial violence, entanglement in the legal system, incarceration, increased injury and illness, and a shortened life span.Reference Gibb, Brewer and Bowden 4 , Reference Kennedy, Altar, Taylor, Degtiar and Hornberger 5 Given the costly and disastrous effects of the schizophrenia spectrum disorders, Emil Kraepelin, who first characterized these psychotic disorders, described them as dementia praecox or early dementia.Reference Kendler 6 In the remainder of this review, we will consider the neurobiology underlying a cluster of brain diseases that can be conceptualized under an umbrella as a group of developmental dementias with similar core pathologies but heterogeneous variations in clinical detail.

The human genome was first published in 2001.Reference Green, Watson and Collins 7 Since then, researchers have been working to identify protein-coding genes. The number of such genes is presently estimated at between 19,000 and 20,000.Reference Amaral, Carbonell-Sala and De La Vega 8 Within the human genome, some 270 gene loci have been associated with schizophrenia spectrum disorders, with 108 risk genes being identified as single nucleotide polymorphisms.Reference Legge, Santoro, Periyasamy, Okewole, Arsalan and Kowalec 9 The most obvious genetic associations have been with genetic variations in the major histocompatibility complex. Besides polymorphisms, structural variants in the form of copy number variants, such as microdeletions and microduplications have a very high impact in a subset of patients. These variations are mainly microdeletions on 1q21.1, 2p16.3, 3q29, 15q13.3, and 16p11.2, as well as a large deletion on 22q11.21 and a microduplication on 16p11.2.Reference Rujescu 10 Importantly, many of the genes and gene loci implicated in schizophrenia are involved in areas such as cell differentiation, cell regulation, cell maturation, cell migration, orientation of cells, the structure of cell receptors, cell adhesion, and, in the case of neurons, development of neural networks.Reference Stauffer, Bethlehem, Dorfschmidt, Won, Warrier and Bullmore 11 , Reference Owen, Legge, Rees, Walters and O’Donovan 12 Additionally, those gene foci that are part of the histocompatibility complex play critical roles in immune identity and control of inflammatory processes.Reference Amaral, Carbonell-Sala and De La Vega 8 , Reference Debnath, Cannon and Venkatasubramanian 13 , Reference Khandaker, Cousins, Deakin, Lennox, Yolken and Jones 14

Although schizophrenia spectrum disorders are heavily genetically determined, it is thought that about 20% of the risk for overt illness is determined by environmental factors such as maternal stress during pregnancy, in utero infection exposure, childhood illnesses, childhood adversity, and childhood or adolescent exposure to drugs such as methamphetamine or cannabis.Reference Kahn, Sommer and Murray 1 , Reference Stilo and Murray 15 Many of these environmental risk factors may influence the occurrence and phenotypic development of schizophrenia via epigenetic processes, such as gene promotion or inhibition of other genes using small peptides or short ribonucleic acid (RNA) sequences, methylation of deoxyribonucleic acid (DNA), or modulation of the acetylation of histone (protein involved in the winding and unwinding of DNA strands for copying).Reference Richetto and Meyer 16 , Reference Srivastava, Dada and Qian 17 Moreover, while no gene therapies currently exist for schizophrenia spectrum disorders, interventions in selected environmental risk factors hold promise for altering the phenotypic presentation of schizophrenia, as well as risk of overt illness in both present and future generations.Reference Xavier, Roman, Aitken and Nixon 18 , Reference Svrakic, Zorumski, Svrakic, Zwir and Cloninger 19

The human central nervous system begins as a simple tube formed from neural crest cells. This relatively simple structure, however, then undergoes a complex and elegant series of steps to become the brain and spinal cord.Reference Lu, Zhang and Lee 20 The brain is formed by overfolding of the cephalad portion of the neural tube with glial cells laying down the structural form of the brain and providing trails of chemical markers for motile neuroblasts to follow to their cortical and subcortical positions.Reference Hendriks, Pagliaro and Andreatta 21 During the second trimester of pregnancy, neuroblasts (immature motile forms of later neurons) undergo rapid mitosis deep in the forming brain near the lateral ventricles. These neuroblasts then crawl to their later positions following neurotrophic markers and organize themselves into orderly neural assemblies.Reference Lu, Zhang and Lee 20 They then form neural networks by sprouting axons and dendrites. Initially, the number of connections is 2 to 5 times greater than the connections present in the mature brain. That is, exposure to the environment and the process of learning selects those pathways that will be reinforced and those that will be allowed to atrophy as the brain matures.Reference Dambska and Laure-Kamionowska 22 -Reference Forde, Ronan and Zwiers 24 The primary visual cortex is the first to mature at about 1 year of age, while the last areas to mature are the frontal and temporal lobes at between 18 the 25 years of age. Thus, the roughly 100 billion neurons of the central nervous system, along with their associated astrocytes, oligodendrogliocytes, and microglia, as well as other cell types, become the adult brain and spinal cord.Reference Hendriks, Pagliaro and Andreatta 21 , Reference Forde, Ronan and Zwiers 24 , Reference Walhovd, Tamnes and Fjell 25

In contrast, brain development and maturation in schizophrenia spectrum disorders is clearly abnormal. To begin, many of the neuroblasts produced during the second trimester of pregnancy fail to reach their correct positions, instead being found in post-mortem studies isolated deep within the white matter of the brain.Reference Connor, Crawford and Akbarian 26 , Reference Wu, Liu and Fang 27 Then, across childhood and adolescence individuals in the premorbid phase of schizophrenia exhibit excessive loss of neurons and synaptic connections, such that by the onset of overt psychosis some one-third to one-half exhibit clear atrophic changes and enlargement of the lateral ventricles on brain imaging.Reference Chung and Cannon 28 , Reference Haukvik, Hartberg and Agartz 29 Ventricular enlargement, reflecting loss of brain tissue in schizophrenia, is illustrated below (Figure 1).

Figure 1. Ventricular enlargement/brain atrophy.

openbooks.lib.msu.edu (open access).

Following the onset of overt illness, loss of brain mass continues and appears to be correlated with the duration of untreated illness and the number of psychotic exacerbations.Reference Kahn, Sommer and Murray 1 , Reference Haukvik, Hartberg and Agartz 29 , Reference Kubota, van Haren and Haijma 30 At least a portion of the brain tissue loss associated with psychotic exacerbations or longer durations of untreated active psychosis appears to be mediated by inflammatory processes, including activation of microglia and invasion of the brain by macrophages.Reference Khandaker, Cousins, Deakin, Lennox, Yolken and Jones 14 , Reference Cai, Catts and Webster 31 , Reference Zhu, Webster and Murphy 32 Interestingly, treatment of high-risk children (i.e., having 2 parents with schizophrenia spectrum disorders) with low-dose antipsychotic medications may reduce the rate of conversion to overt illness in adolescence.Reference Yung and Nelson 33 Nevertheless, it should be noted that some subsequent studies have failed to find evidence that antipsychotic treatment during the premorbid phase of schizophrenia is protective with respect to later development of overt schizophrenia.Reference Zhang, Xu and Tang 34 Better established appear to be observations that consistent antipsychotic treatment (eg, with LAIs) slows but does not reverse the deterioration of the brain in schizophrenia spectrum disorders.Reference Horvitz-Lennon, Predmore and Orr 35 -Reference Lawrie 37

Clinically, the signs and symptoms of schizophrenia have been divided into positive, negative, and cognitive deficit domains.Reference Kahn, Sommer and Murray 1 , Reference McCutcheon, Reis Marques and Howes 38 Positive signs and symptoms include hallucinations/illusions, delusional ideation, illogical thoughts and behavior, hyperactivity/agitation, and thought disorder.Reference Kahn, Sommer and Murray 1 , Reference McCutcheon, Reis Marques and Howes 38 Negative signs and symptoms include apathy, lethargy, abulia, avolition, and social withdrawal.Reference Marder and Kirkpatrick 39 Cognitive deficits in schizophrenia spectrum disorders include deficits in attention, concentration, memory organization and recall, language processing, and executive functions such as self-awareness and social judgment.Reference McCutcheon, Reis Marques and Howes 38 , Reference Javitt 40 In addition to the developmental abnormalities and atrophic brain changes described earlier in this article, 2 neuromodulatory molecules, that is, dopamine and serotonin, appear to play important functional roles in schizophrenia spectrum disorders.Reference Stahl 41 , Reference Cumming, Abi-Dargham and Gründer 42 Below, we will consider 3 neural networks with respect to the positive, negative, and cognitive domains of schizophrenia.

Positive signs and symptoms appear to arise in part from excessive dopamine stimulation of mesostriatal projections to temporal lobe association cortices and related structures (formerly termed the mesolimbic pathway).Reference Stahl 41 , Reference Howes and Shatalina 43 This excessive stimulation of limbic D2 dopamine receptors, in turn, appears to arise from a failure of inhibition by gamma aminobutyric (GABA) interneurons in the frontal cortex. And failure of M4 acetylcholine receptors on the cell bodies of the relevant mesostriatal dopamine neurons.Reference Stahl 41 , Reference Foster, Bryant and Conn 44 This is illustrated as follows (Figure 2).

Figure 2. Mesostriatal dopaminergic hyperactivity.

Stahl, S. Stahl’s Essential Psychopharmacology, 5th Edition, Chapter 4, p. 93.

Excessive serotonin (5-hydroxytryptamine) stimulation of 5HT2A receptors may add to positive psychotic signs and symptoms, especially visual hallucinations, in schizophrenia.Reference Stahl 41 , Reference Preller, Burt and Ji 45 This is illustrated as follows (Figure 3).

Figure 3. 5HT2A serotonergic hyperactivity.

Stahl, S. Stahl’s Essential Psychopharmacology, 5th Edition, Chapter 4, p. 136.

Finally, it appears that in addition to previously described developmental pathologies and atrophic changes, inadequate stimulation of frontal lobe D1 and D3 dopamine receptors contributes to the negative symptoms and cognitive impairments of schizophrenia spectrum disorders, including anosognosia (unawareness of illness).Reference Stahl 41 , Reference Howes and Kapur 46 This is illustrated as follows (Figure 4).

Figure 4. Mesocortical dopaminergic hypoactivity.

Stahl, S. Stahl’s Essential Psychopharmacology, 5th Edition, Chapter 4, p. 95.

Importantly, all antipsychotic medications appear capable of ameliorating psychotic symptoms, with the largest effects being on positive signs and symptoms.Reference Sabe, Pillinger and Kaiser 47 In particular, LAIs appear superior in preventing relapse and, thereby, illness progression, morbidity, and mortality.Reference Horvitz-Lennon, Predmore and Orr 35 , Reference Taipale, Mittendorfer-Rutz and Alexanderson 48 In the near future, a new class of antipsychotics likely starting with xanomeline/trospium may be able to presynaptically modulate dopamine release in mesostriatal projections by targeting the M4 acetylcholine auto-receptor.Reference Foster, Bryant and Conn 44 Among the antipsychotics, clozapine remains the “gold standard” of treatment in several areas, that is, management of treatment-resistant illness, reduction of violence, reduction of suicide risk, and enhancement of cognitive executive functions.Reference Meltzer and McGurk 49 , Reference Stahl 50 Clozapine also appears to be unique in that it likely acts by exerting effects upstream of the mesostriatal dopamine neurons by improving glutamate signal transduction.Reference Nucifora, Woznica, Lee, Cascella and Sawa 51 , Reference McQueen, Sendt and Gillespie 52

Summary: Schizophrenia spectrum disorders are a group of related psychotic developmental dementias (dementia praecox) characterized by positive, negative, and cognitive signs and symptoms usually beginning in adolescence or early adulthood. Illness is mediated by a combination of developmental and atrophic changes in brain structure and defects in the signal transductions of glutamate, gamma amino butyric acid (GABA), acetylcholine, dopamine, and serotonin. Importantly, defects in neurotransmitter signal transduction provide targets for pharmacotherapy with antipsychotic medications. Critically, failure to provide consistent antipsychotic treatment early in the course of illness (eg, with LAIs) promotes atrophic brain pathology and deterioration of the illness course. Finally, while all antipsychotic medications can ameliorate acute signs and symptoms, clozapine shows superior efficacy in treating the positive, negative, and cognitive signs and symptoms of the schizophrenia spectrum disorders, as well as treatment resistance, violence, and suicide.

Acknowledgement

Ngoc Tram Vo, D.O. for manuscript review and constructive suggestions.

Author contributions

Writing – original draft: S.M.S., A.W.A., M.A.C.

Disclosure

Dr. Arias and Dr. Cummings report no disclosures. Dr. Stahl reports having received advising fees, consulting fees, speaking fees, and/or research grants from Acadia, Alkermes, Biomarin, Clintara, Eli-Lilly, EnVivo, Forest, Forum, GenoMind, JayMac, Lundbeck, Merck, Novartis, Orexigen, Otsuka-USA, PamLabs, Pfizer, RCT Logic, Servier, Shire, Sprout, Sunovion, Sunovion-UK, Taisho, Takeda, Teva, Tonix, and Trius.

References

Kahn, RS, Sommer, IE, Murray, RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067.CrossRefGoogle ScholarPubMed
McGrath, J, Saha, S, Chant, D, Welham, J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:6776.CrossRefGoogle ScholarPubMed
Kadakia, A, Catillon, M, Fan, Q, et al. The economic burden of schizophrenia in the United States. J Clin Psychiatry. 2022;83(6):22M14458.CrossRefGoogle ScholarPubMed
Gibb, S, Brewer, N, Bowden, N. Social impacts and costs of schizophrenia: a national cohort study using New Zealand linked administrative data. New Zealand Med J. 2021;134:6683.Google ScholarPubMed
Kennedy, JL, Altar, CA, Taylor, DL, Degtiar, I, Hornberger, JC. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol. 2014;29:6376.CrossRefGoogle ScholarPubMed
Kendler, KS. The development of Kraepelin’s concept of dementia praecox: a close reading of relevant texts. JAMA Psychiatry. 2020;77:11811187.CrossRefGoogle ScholarPubMed
Green, ED, Watson, JD, Collins, FS. Human genome project: twenty-five years of big biology. Nature. 2015;526:2931.CrossRefGoogle ScholarPubMed
Amaral, P, Carbonell-Sala, S, De La Vega, FM, et al. The status of the human gene catalogue. Nature. 2023;622:4147.CrossRefGoogle ScholarPubMed
Legge, SE, Santoro, ML, Periyasamy, S, Okewole, A, Arsalan, A, Kowalec, K. Genetic architecture of schizophrenia: a review of major advancements. Psychol Med. 2021;51:21682177.CrossRefGoogle ScholarPubMed
Rujescu, D. Search for risk genes in schizophrenia. Der Nervenarzt. 2017;88:751754.CrossRefGoogle ScholarPubMed
Stauffer, EM, Bethlehem, RAI, Dorfschmidt, L, Won, H, Warrier, V, Bullmore, ET. The genetic relationships between brain structure and schizophrenia. Nat Commun. 2023;14:7820.CrossRefGoogle ScholarPubMed
Owen, MJ, Legge, SE, Rees, E, Walters, JTR, O’Donovan, MC. Genomic findings in schizophrenia and their implications. Mol Psychiatry. 2023;28:36383647.CrossRefGoogle ScholarPubMed
Debnath, M, Cannon, DM, Venkatasubramanian, G. Variation in the major histocompatibility complex [MHC] gene family in schizophrenia: associations and functional implications. Prog Neuropsychopharmacol Biol Psychiatry. 2013;42:4962.CrossRefGoogle ScholarPubMed
Khandaker, GM, Cousins, L, Deakin, J, Lennox, BR, Yolken, R, Jones, PB. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry. 2015;2:258270.CrossRefGoogle Scholar
Stilo, SA, Murray, RM. Non-genetic factors in schizophrenia. Curr Psychiatry Rep. 2019;21:100.CrossRefGoogle ScholarPubMed
Richetto, J, Meyer, U. Epigenetic modifications in schizophrenia and related disorders: molecular scars of environmental exposures and source of phenotypic variability. Biol Psychiatry. 2021;89:215226.CrossRefGoogle ScholarPubMed
Srivastava, A, Dada, O, Qian, J, et al. Epigenetics of schizophrenia. Psychiatry Res. 2021;305:114218.CrossRefGoogle ScholarPubMed
Xavier, MJ, Roman, SD, Aitken, RJ, Nixon, B. Transgenerational inheritance: how impacts to the epigenetic and genetic information of parents affect offspring health. Human Reprod Update. 2019;25:518540.CrossRefGoogle Scholar
Svrakic, DM, Zorumski, CF, Svrakic, NM, Zwir, I, Cloninger, CR. Risk architecture of schizophrenia: the role of epigenetics. Curr Opin Psychiatry. 2013;26:188195.CrossRefGoogle ScholarPubMed
Lu, Z, Zhang, M, Lee, J, et al. Tracking cell-type-specific temporal dynamics in human and mouse brains. Cell. 2023;186:43454364.e24.CrossRefGoogle ScholarPubMed
Hendriks, D, Pagliaro, A, Andreatta, F, et al. Human fetal brain self-organizes into long-term expanding organoids. Cell. 2024;187:712732.e38.CrossRefGoogle ScholarPubMed
Dambska, M, Laure-Kamionowska, M. Myelination as a parameter of normal and retarded brain maturation. Brain Dev. 1990;12:214220.CrossRefGoogle ScholarPubMed
Holzer, L, Halfon, O, Thoua, V. La maturation cérébrale à l’adolescence [Adolescent brain maturation]. Archives de pediatrie: organe officiel de la Societe francaise de pediatrie. 2011;18:579588.CrossRefGoogle Scholar
Forde, NJ, Ronan, L, Zwiers, MP, et al. Healthy cortical development through adolescence and early adulthood. Brain Struct Funct. 2017;222:36533663.CrossRefGoogle ScholarPubMed
Walhovd, KB, Tamnes, CK, Fjell, AM. Brain structural maturation and the foundations of cognitive behavioral development. Curr Opin Neurol. 2014;27:176184.CrossRefGoogle ScholarPubMed
Connor, CM, Crawford, BC, Akbarian, S. White matter neuron alterations in schizophrenia and related disorders. Int J Dev Neurosci. 2011;29:325334.CrossRefGoogle ScholarPubMed
Wu, Q, Liu, J, Fang, A, et al. The dynamics of neuronal migration. Adv Exp Med Biol. 2014;800:2536.CrossRefGoogle ScholarPubMed
Chung, Y, Cannon, TD. Brain imaging during the transition from psychosis prodrome to schizophrenia. J Nerv Ment Dis. 2015;203:336341.CrossRefGoogle ScholarPubMed
Haukvik, UK, Hartberg, CB, Agartz, I. Schizophrenia--what does structural MRI show? Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. 2013;133:850853.CrossRefGoogle Scholar
Kubota, M, van Haren, NE, Haijma, SV, et al. Association of IQ changes and progressive brain changes in patients with schizophrenia. JAMA Psychiatry. 2015;72:803812.CrossRefGoogle ScholarPubMed
Cai, HQ, Catts, VS, Webster, MJ, et al. Increased macrophages and changed brain endothelial cell gene expression in the frontal cortex of people with schizophrenia displaying inflammation. Mol Psychiatry. 2020;25:761775.CrossRefGoogle ScholarPubMed
Zhu, Y, Webster, MJ, Murphy, CE, et al. Distinct phenotypes of inflammation associated macrophages and microglia in the prefrontal cortex schizophrenia compared to controls. Front Neurosci. 2022;16:858989.CrossRefGoogle Scholar
Yung, AR, Nelson, B. Young people at ultra high risk for psychosis: research from the PACE clinic. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2011;33(Suppl 2):s143s160.CrossRefGoogle ScholarPubMed
Zhang, T, Xu, L, Tang, X, et al. Real-world effectiveness of antipsychotic treatment in psychosis prevention in a 3-year cohort of 517 individuals at clinical high risk from the SHARP (ShangHai At Risk for Psychosis). Aust N Z J Psychiatry. 2020;54:696706.CrossRefGoogle Scholar
Horvitz-Lennon, M, Predmore, Z, Orr, P, et al. The predicted long-term benefits of ensuring timely treatment and medication adherence in early schizophrenia. Adm Policy Ment Health. 2020;47:357365.CrossRefGoogle ScholarPubMed
Hunsberger, J, Austin, DR, Henter, ID, Chen, G. The neurotrophic and neuroprotective effects of psychotropic agents. Dialogues Clin Neurosci. 2009;11:333348.CrossRefGoogle ScholarPubMed
Lawrie, SM. Do antipsychotic drugs shrink the brain? Probably not. J Psychopharmacol (Oxford, England). 2022;36:425427.CrossRefGoogle ScholarPubMed
McCutcheon, RA, Reis Marques, T, Howes, OD. Schizophrenia-an overview. JAMA Psychiatry. 2020;77:201210.CrossRefGoogle ScholarPubMed
Marder, SR, Kirkpatrick, B. Defining and measuring negative symptoms of schizophrenia in clinical trials. Eur Neuropsychopharmacol. 2014;24:737743.CrossRefGoogle ScholarPubMed
Javitt, DC. Cognitive impairment associated with schizophrenia: from pathophysiology to treatment. Annu Rev Pharmacol Toxicol. 2023;63:119141.CrossRefGoogle ScholarPubMed
Stahl, SM. Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate. CNS Spectr. 2018;23:187191.CrossRefGoogle ScholarPubMed
Cumming, P, Abi-Dargham, A, Gründer, G. Molecular imaging of schizophrenia: neurochemical findings in a heterogeneous and evolving disorder. Behav Brain Res. 2021;398:113004.CrossRefGoogle Scholar
Howes, OD, Shatalina, E. Integrating the neurodevelopmental and dopamine hypotheses of schizophrenia and the role of cortical excitation-inhibition balance. Biol Psychiatry. 2022;92:501513.CrossRefGoogle ScholarPubMed
Foster, DJ, Bryant, ZK, Conn, PJ. Targeting muscarinic receptors to treat schizophrenia. Behav Brain Res. 2021;405:113201.CrossRefGoogle ScholarPubMed
Preller, KH, Burt, JB, Ji, JL, et al. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. eLife. 2018;7:E35082.CrossRefGoogle Scholar
Howes, OD, Kapur, S. The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull. 2009;35:549562.CrossRefGoogle ScholarPubMed
Sabe, M, Pillinger, T, Kaiser, S, et al. Half a century of research on antipsychotics and schizophrenia: a scientometric study of hotspots, nodes, bursts, and trends. Neurosci Biobehav Rev. 2022;136:104608.CrossRefGoogle ScholarPubMed
Taipale, H, Mittendorfer-Rutz, E, Alexanderson, K, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophrenia Res. 2018;197:274280.CrossRefGoogle Scholar
Meltzer, HY, McGurk, SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 1999;25:233255.CrossRefGoogle ScholarPubMed
Stahl, SM. Clozapine: is now the time for more clinicians to adopt this orphan? CNS Spectr. 2014;19:279281.CrossRefGoogle ScholarPubMed
Nucifora, FC, Woznica, E, Lee, BJ, Cascella, N, Sawa, A. Treatment resistant schizophrenia: clinical, biological, and therapeutic perspectives. Neurobiol Dis. 2019;131:104257.CrossRefGoogle ScholarPubMed
McQueen, G, Sendt, KV, Gillespie, A, et al. Changes in brain glutamate on switching to clozapine in treatment-resistant schizophrenia. Schizophr Bull. 2021;47:662671.CrossRefGoogle ScholarPubMed
Figure 0

Figure 1. Ventricular enlargement/brain atrophy.openbooks.lib.msu.edu (open access).

Figure 1

Figure 2. Mesostriatal dopaminergic hyperactivity.Stahl, S. Stahl’s Essential Psychopharmacology, 5th Edition, Chapter 4, p. 93.

Figure 2

Figure 3. 5HT2A serotonergic hyperactivity.Stahl, S. Stahl’s Essential Psychopharmacology, 5th Edition, Chapter 4, p. 136.

Figure 3

Figure 4. Mesocortical dopaminergic hypoactivity.Stahl, S. Stahl’s Essential Psychopharmacology, 5th Edition, Chapter 4, p. 95.